drugset / Trial / NCT02850744
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
Phase 2
Terminated
10 enrolled
PIQUR Therapeutics AG
Insel Gruppe AG, University Hospital Bern · collabUniversity Hospital, Basel, Switzerland · collabUniversity Hospital, Zürich · collab
NaSingle-groupOpen-labelTreatment
Summary
PQR309 is an oral, dual pan-PI3K (phosphatidylinositol 3-kinase phosphoinositide 3-kinase) and mTOR (mammilian target of rapamycin) inhibitor that penetrates the blood-brain barrier at pharmacodynamically active concentrations. This study plans to evaluate PQR309 in treatment of patients with first progression of glioblastoma.
Timeline
- Start
- 2015-07
- Primary completion
- 2017-11
- Completion
- 2017-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimiralisib | Small molecule | 80 mg | Oral |